# US 2019/0169190 A1 · Small molecules for the treatment of primary cancer and cancer metastasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169190 A1
- Document ID: US20190169190A1
- Status: Published application
- Kind: A1
- Application number: 16/267,106
- Filed: 2019-02-04
- Published: 2019-06-06
- Earliest claimed: 2015-01-17
- Assignees: Board of Regents, The University of Texas System
- Inventors: Jean X JIANG
- Web page: https://patentgrep.com/patent/US20190169190A1

## CPC

- C07D 473/06: with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 35/00: Antineoplastic agents
- C07D 473/34: attached in position 6, e.g. adenine
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Certain embodiments are directed to non-hydrolysable ATP analogs and adenosine receptor antagonists that inhibit migration and growth of cancer cells.

## Claims

### Claim 1

A compound that is a chemical analog of non-hydrolysable adenosine ATP analog 5′-[γ-thio]triphosphate (ATPγS) with general formula of Formula: I
where R1 and R2 are independently selected from hydrogen, cyano, C1 to C3 alkyl, halo, or heteromethyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is selected from hydrogen, cyano, C1 to C3 alkyl, halo, or heteromethyl, and R2 is a hydrogen or halogen.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is a hydrogen, fluoro, methyl, cyano, or trifluoromethyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is cyano and R2 is hydrogen, R1 is hydrogen and R2 is hydrogen, R1 is trifluoromethyl and R2 is hydrogen, R1 methyl and R2 is hydrogen, and R1 is fluoro and R2 is fluoro.

### Claim 5 (depends on 1)

A method for treating a cancer patient comprising administering to the patient an effective amount of a one or more compounds of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is breast cancer.

### Claim 7 (depends on 1, 5)

The method of claim 5, wherein one or more compounds of claim 1 are administered intravenously.

### Claim 8 (depends on 1, 5)

The method of claim 5, wherein one or more compounds of claim 1 are administered orally.

### Claim 9

A compound that is a chemical analog of adenosine receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine with general formula of Formula II
where R3 is a heteromethyl, cycloalkyl, or tetrahydrofuran.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R3 is difluoro methyl, cyclopropyl, cyclobutyl, or β-tetrahydrofuran.

### Claim 11 (depends on 9)

A method for treating a cancer patient comprising administering to the patient an effective amount of one or more compounds of claim 9.
